Researchers and Instructors

Tameka A. Jennings

Tameka A. Jennings

Clinical Assistant Professor

J. William Fulbright College of Arts & Sciences

(BISC)-Biological Sciences

Phone: 479-575-8735

Download vcard

Map

Breast cancer, endocytosis, HER2, obesity linked cancer initiation and progression.

Ph.D. University of Arkansas, Cell and Molecular Biology Program

Bailey, T.A., Luan, H., Tom, E., Bielecki, T., Ahmad, G.,George, M., Kelly, D., Naratarajan, A., Raja,S.M., Band, V., Band, H. 2013.  A kinase inhibitor screen identifies PKC-a as a promoter of endocytic recycling of ErbB2 in breast cancer cells (manuscript submitted for review) 

Bailey, T.A., Luan, H., Clubb, R.J., Naramura, M., Band,V., Raja,S.M., Band, H. 2011.  Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. Journal of Carcinogenesis; 2011; 10:28. Epub 2011 Nov 30

Ortega-Cava, C.F.,  Raja,S.M.,  Laiq, Z., Bailey, T.A., Luan, H., Mohapatra,B., Williams, S.H., Ericsson, A.C., Goswami,R.,  Dimri,  M., Duan, L., Band,V., Naramura, M., Band, H. 2011. Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer. Journal of Carcinogenesis; 2011; 10:29. Epub 2011 Nov 30.

Raja, S.M., Clubb, R.J., Ortega-Cava, C., Williams, S., Bailey, T., Duan, L., Zhao, X.,  Reddi, A. L., Nyong, A.M., Natarajan, A., Band, V., and Band, H. 2011. Anticancer activity of celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.  Cancer Biology and Therapy; 11:263-276.